Drug Type Oligonucleotide |
Synonyms Oral LNC-Delivered Small Oligonucleotides |
Target |
Mechanism IL-17A inhibitors(Interleukin 17A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Psoriasis | Preclinical | US | 27 Dec 2023 |